Skip to content
value.today

Neogene Therapeutics, Inc.

🇺🇸 New York, New York, USABiotechnologyFounded 2018
Total raised
$125 M
2 rounds on record
Latest round
$110 M
Sep 2020
First round on record
May 2019
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Neogene Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2020$110 MNo. 2$50 to $250 million

Neogene Therapeutics, Inc.: Raise no. 2, Sep 2020

Investors in this round

63 investors had bought by the notice of Sep 14, 2020: 63 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$110 M of $110 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carsten Linnemann, PhD · Executive Officer, Director, Promoter
  • Antonius N.M. Schumacher · Director
  • Caroline N.M. Stout · Director
  • David Tanen · Director, Promoter
  • Elisa N.M. Petris · Director
  • Franz N.M. Humer · Director
  • Katherine Wood · Director
  • Rachel N.M. Mears · Director
  • Rajul Jain · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David M. Tanen, Corporate Secretary. Source: SEC Form D, newest notice filed Sep 14, 2020. Read the notice at the SEC.

equitySEC
May 2019$15 MNo. 1$10 to $50 million

Neogene Therapeutics, Inc.: Raise no. 1, May 2019

Investors in this round

42 investors had bought by the notice of May 23, 2019: 42 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carsten Linnemann, PhD · Executive Officer, Director, Promoter
  • Antonius N.M. Schumacher · Director
  • David M. Tanen · Director, Promoter
  • Fei M. Chen · Director
  • Helen M. Kim · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David M. Tanen, Corporate Secretary. Source: SEC Form D, newest notice filed May 23, 2019. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Neogene Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2020).

    SEC Form D · Sep 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2020

That is all the official record says: Neogene Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Neogene Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 63 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Neogene Therapeutics, Inc.
NameRoleNamed in
Carsten Linnemann, PhDExecutive officerSep 2020
Antonius N.M. SchumacherDirectorSep 2020
Caroline N.M. StoutDirectorSep 2020
Carsten Linnemann, PhDDirectorSep 2020
David TanenDirectorSep 2020
Elisa N.M. PetrisDirectorSep 2020
Franz N.M. HumerDirectorSep 2020
Katherine WoodDirectorSep 2020
Rachel N.M. MearsDirectorSep 2020
Rajul JainDirectorSep 2020
David M. TanenDirectorMay 2019
Fei M. ChenDirectorMay 2019
Helen M. KimDirectorMay 2019
Carsten Linnemann, PhDPromoterSep 2020
David TanenPromoterSep 2020
David M. TanenPromoterMay 2019